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INTRODUCTION 
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INTRODUCTION 
Pregnancy is a hypercoagulable state with an increased tendency of 
thrombus formation.  In normal pregnancy, successful implantation depends on the 
maternal endometrium receptivity. It is influenced by the synergistic actions of 
progesterone and nitric oxide. Pregnancy is accompanied by considerable 
physiological changes in the maternal cardio vascular system which includes 
increased uterine blood flow, altered response to vasopressor agents and reduced 
peripheral resistance and blood pressure. These changes confirm the adequacy of 
oxygen and nutrient delivery to the fetus. 
As per the estimates of World Health Organisation, the global incidence of 
preeclampsia is 5% to 7% and in India it‟s reported in 8-10% of all pregnancies. In 
developing and developed countries, preeclampsia is one of the leading causes of 
maternal mortality and morbidity.  It is associated with increased vascular 
reactivity and vasoconstriction and is characterized by placental abnormalities and 
maternal vascular endothelial dysfunction.  The maternal syndrome of 
preeclampsia is characterized by hypertension, proteinuria, edema, abnormal 
clotting and impaired liver and renal function. These are explained by generalized 
vascular endothelial cell dysfunction. 
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Preeclampsia is defined as the presence of blood pressure higher than 
140/90mmHg on two occasions more than six hours  apart and proteinuria of 300 
mg/24hr after the twentieth (20
th
 week of pregnancy. Genetic involvement in the 
preeclampsia, has long been recognized but the mode of inheritance and the genes 
involved has not been straightforward. The association of nitric oxide 3 gene 
polymorphisms and preeclampsia-risk states that it is a clinical syndrome 
characterized by new-onset of hypertension and proteinuria after 20 weeks of 
gestation
1
. It afflicts 3–5% of pregnancies and is a major cause of maternal and 
prenatal morbidity and mortality worldwide
 2
. Essential in the pathogenesis of 
preeclampsia is endothelial dysfunction due to impaired trophoblast invasion and 
spiral artery remodelling, resulting in abnormal implantation and placental hypo-
perfusion
3
.  
Although some dietary, environmental and genetic factors of preeclampsia 
have been identified, its mechanism is still not clear; therefore, its prevention 
remains a challenge
4
. Family-based studies have shown that genetic factors may 
play a role in preeclampsia 
5
. In addition, candidate-gene association studies (CAS) 
on preeclampsia have not produced conclusive results so far 
6
. 
As a potent vasodilator, circulating nitric oxide (NO) plays a crucial role in 
endothelial function regulation, blood pressure control and cardiovascular 
homeostasis
7
.  
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Endothelial nitric oxide synthase (eNOS) is an enzyme which synthesizes 
NO constitutively via catalyzing the conversion of L-arginine to L-citrulline. 
Endothelial NO availability is largely regulated by its synthesis by eNOS. The 
gene that encodes eNOS, NOS3, is therefore considered as a candidate gene for 
preeclampsia 
8
. 
However, the pathogenesis of preeclampsia is poorly understood and the 
search for low penetrant genes by hypothesis driven candidate-gene studies 
(genetic association study-GAS) and hypothesis-free genome-wide association 
studies is ongoing 
9
. 
The leading hypotheses, concerning the pathogenesis of preeclampsia, are 
based on disturbed placental function and impaired remodelling of the spiral 
arteries 
10
.Endothelial nitric oxide synthase (NOS3) is an important regulator of 
vascular tone and contributes to the reduction of the uteroplacental resistance seen 
in normal pregnancy
11
. Therefore, the endothelial nitric oxide synthase gene 
(NOS3), located at the 7q35-q36 region, has emerged as a logical candidate gene in 
the development of preeclampsia. Variants (polymorphisms) of the NOS3 gene 
have been investigated for their association with preeclampsia and other disorders 
such as hypertension.  
4 
 
The three most common variants examined for clinical relevance, based on 
their potential functional effects are (i) a G894T substitution in exon 7 resulting in 
a Glu to Asp substitution at codon 298 (rs1799983), (ii) an insertion-deletion in 
intron 4 (4a/b) consisting of two alleles (the a*-deletion which has four tandem 27-
bp repeats and the b*-insertion having five repeats), and (iii) a T786C substitution 
in the promoter region (rs2070744). A whole genome-scan meta-analysis for 
preeclampsia has already identified the locus of NOS3 gene as a promising 
candidate for preeclampsia susceptibility.
 
GAS that investigated the association between NOS3 variants and 
preeclampsia has produced controversial or in conclusive results and the 
replication record of these studies is relatively poor. Therefore, the status of 
association for the NOS3 variants remains ambiguous.  
The significance of - 786T > C polymorphism of endothelial NO synthase 
(eNOS) gene in severe preeclampsia is believed to be induced by endothelial cell 
dysfunction in placenta. Highly polymorphic endothelial nitric oxide synthase 
(eNOS) activity belongs to the factors significantly influencing vasomotor tone in 
placenta and PE susceptibility. The presence of mutated homozygous CC genotype 
and C allele of -786T/C polymorphism of eNOS gene influences the higher 
susceptibility to develop severe Preeclampsia development
12
.  Thus the topic for 
this research was decided. 
  
 
REVIEW OF 
LITERATURE 
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REVIEW OF LITERATURE 
Epidemiology 
A standard evaluation by the World Health Organization indicates that 
hypertensive disorders account for 16% of all maternal deaths in developed 
countries, 9%  in Africa and Asia, and as high as 26% in Latin America and the 
Caribbean 
13
.  
Context India  
Occurrence of hypertensive disorders in India is found to be 10.08 % as 
noticed through the data collected by the National Eclampsia Registry (NER) 
(11,266 out of 1,11,725 deliveries). Over the past 3 years, 2,554 patients out of 
11,266 are presented with eclampsia.  The FOGSI-ICOG NER has conducted forth 
some revealing trends. Eclampsia generality among registry patients was 1.9 %. 
National sample surveys in the past have shown prevalence to be 1–5 %. This is 
out of the 1,11,725 deliveries examined from the cases reported by 175 reporting 
centers. Number of eclampsia-cases is more than imminent eclampsia-cases. This 
points to the lost opportunities of prevention.  
As per the NER data, preeclampsia was mostly diagnosed among 
asymptomatic (57 %) patients; 22 % had headache and very few had vomiting, 
epigastric pain, giddiness, etc.  Antenatal eclampsia is noted to be common 
(76.78 %); however, post-partum convulsions (13.72 %) are also significant 
14
. 
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Fetal and neonatal effects 
Fetal and neonatal outcomes related to preeclampsia vary around the world. 
Approximately 12–25% of fetal growth reduction and small-for-gestational-age 
infants and 15–20% of all preterm births are attributable to preeclampsia15. 
Recurrence in subsequent pregnancies 
Studies have reported that there is a 7–20% chance of preeclampsia 
recurrence in an upcoming pregnancy
16
.This risk is further increased if a woman 
has had two prior preeclamptic pregnancies and is also pretended by the gestational 
age of onset
17
. 
The American College of Obstetricians and Gynecologists (the College) 
Task Force on Hypertension in Pregnancy had been using the classification schema 
first initiated in 1972 by the College and modified in 1990 and 2000 and also 
incorporating the reports of the National High Blood Pressure Education Program 
Working Group
18
. Similar classifications can be found in the American Society of 
Hypertension guidelines, as well as College Practice Bulletins 
19
. Although the task 
force has adjusted a few of the parts of the groups, it continues with this 
fundamental, accurate, and practical classification, which considers hyper- tension 
during pregnancy in only four categories: 
 
1) Preeclampsia–eclampsia,  
2) Chronic hypertension (of any cause),  
3) Chronic hypertension with superimposed preeclampsia 
4) Gestational hypertension.  
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Preeclampsia–Eclampsia 
Preeclampsia is a pregnancy-specific hypertensive disease, diagnosed only 
after 20 weeks of gestation, with multitask involvement. It is characterized by 
hypertension and proteinuria. Preeclampsia is thought to grow as a result of poor 
placentation, causing endothelial dysfunction, disordered angiogenic balance and 
resultant hypertension, glomerular lesions and hepatic failure.  However, some 
women present with hypertension and multi systemic signs usually indicative of 
disease severity in the absence of proteinuria.  
Hypertension is defined as either a systolic BP of 140 mm Hg or greater, a 
diastolic BP of 90 mm Hg or greater, or both.  Proteinuria is diagnosed when 24-
hour excretion equals or exceeds 300 mg in 24 hours or the ratio of measured 
protein to creatinine in a single voided urine measures or exceeds 3.0 (each 
measured as mg/dL), termed as protein/creatinine ratio.  
Eclampsia is the convulsive phase of the disorder and more severe 
indication of the disease. It is frequently preceded by precursory events, such as 
serious headaches and hyper-reflexia, but it can also occur in the absence of 
warning signs or symptoms. 
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Chronic Hypertension 
Chronic hypertension in pregnancy is defined as high BP known to predate 
category or detected before 20 weeks of gestation. Previously, it was suggested 
that chronic hypertension indicated high BP diagnosed in the first half of 
pregnancy and modified postpartum. 
 
Chronic Hypertension with Superimposed Preeclampsia 
Preeclampsia may complicate all other hypertensive disorders, and in fact 
the incidence is forty five times higher than in non-hypertensive pregnant 
women
20
. In such cases, prognosis for the woman and her fetus is worse, while 
evidence from renal biopsy studies recommend that the diagnosis of 
superimposed preeclampsia may be often erroneous
21
. 
 
Gestational Hypertension 
Gestational hypertension is characterized by new-onset elevations of BP 
after 20 weeks of gestation, often near term, in the absence of accompanying 
proteinuria. The failure of BP to normalize postpartum requires changing the 
diagnosis to chronic hypertension
22
. 
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Postpartum Hypertension  
It is important to remember that preeclampsia, including preeclampsia with 
severe systemic organ action and seizures, can first develop in the postpartum 
period. Since early hospital discharge is the current practice, this mandates to 
instruct the women discharged from the hospital to be aware of symptoms (eg. 
severe headache, visual disturbances, or epigastric pain) that should be detailed to 
a health care provider. 
 
Risk factors for preeclampsia 
The epidemiology of preeclampsia reflects a broad range of risk factors as 
well as the complexity and heterogeneity of the disease. Risk factors can be 
classified into pregnancy-certain features and maternal pre-existing features. The 
incidence of preeclampsia is increasing and may be associated to the higher 
prevalence of predisposing disorders such as hypertension, diabetes, obesity, delay 
in child-bearing, and the use of artificial reproductive technologies with associated 
increase in multi-fetal gestation
23
. 
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Common risk factors for preeclampsia 
(i) Pregnancy-specific issues 
 Nuiparity 
 Partner-related factors (new paternity, limited sperm exposure (e.g., barrier 
contraception) 
 Multiple pregnancy 
 Hydatidiform mole 
 
(ii) Maternal pre-existing conditions 
 Older age 
 African-American race 
 Higher body mass index 
 Pregestational diabetes 
 Chronic hypertension 
 Renal disease 
 Antiphospholipid antibody syndrome 
 Connective tissue disorder (e.g. systemic lupus erythematosus) 
 Family history or preeclampsia 
 Lack of smoking 
 
11 
 
HELLP syndrome: 
The HELLP syndrome is a major problem in pregnancy characterized by 
hemolysis, elevated liver enzymes and low platelet count, occurring in 0.5 to 0.9% 
of all pregnancies and in 10 – 20% of cases with severe preeclampsia. The present 
evaluation highlights occurrence, diagnosis, complications, surveillance and 
corticosteroid treatment, mode of delivery and risk of recurrence 
24
. 
 
NITRIC OXIDE 
The endothelium plays a central role in the regulation of vascular tone and 
blood flow, by the secretion and capture of paracrine vasoactive substances, which 
includes vasodilator substances (NO, prostacyclin & endothelium-derived 
hyperpolarising factor) and vasoconstrictor substances (endothelin-1, thromboxane 
A2 & platelet-activating factor). 
NO is the main mediator of vasomotor tone regulation in physiological 
circumstances, small amount being continuously secreted by the endothelial cells 
25
. To maintain a reduced arterial tone in the systemic and pulmonary circulation 
26
. 
The vasodilator activity of NO is due to its interaction with the iron atom of the 
heme- prosthetic group of cyclic guanosine monophosphate (cGMP) 
27
. In smooth 
muscle cells, this decreases intracellular calcium concentration, causing vascular 
relaxation 
28
. 
 
  
Figure 1:  
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Endothelial dysfunction is characterized by the reduction of the 
endothelium-derived vasodilators, by local increases in antagonists to these 
substances or by an association of two factors. Endothelial dysfunction appears to 
play a pathogenic role in the initial development of atherosclerosis  and of unstable 
coronary syndromes, and their diverse risk factors viz hypercholesterolemia 
smoking, hypertension, diabetes mellitus, family history of premature coronary 
disease, hyperhomocysteinemia
 
and aging. 
NO and endothelin are the two major factors involved in endothelial 
dysfunction. High plasma concentrations of  Endothelin-1 have been reported in 
myocardial infarction, cardiogenic shock, unstable angina pectoris, coronary artery 
disease in general, cardiac failure and essential hypertension 
29
. Endothelin-1 
action, unopposed by NO, tends to stimulate vasoconstriction and proliferation of 
vascular smooth muscle cells in conditons in endothelial dysfunction 
30
. 
Reduction in synthesis or local availability of NO have been frequently 
considered the most important causes of endothelial dysfunction in various clinical 
conditions. NO release from the endothelium, is decreased in patients with 
established coronary atherosclerosis and hypertension 
31.
  
 
  
  
Figure 2: 
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NITRIC OXIDE PATHWAY: 
  NO is produced by the enzymenitric oxide synthase (NOS) 
32
 which 
catalyzes a five electron oxidation of a guanidino nitrogen of L - arginine (L - 
Arg). Oxidation of L-Arg to L–citrulline occurs via two successive mono -
oxygenation reactions producing N
G 
hydroxy L – arginine as an intermediate. Two 
moles of O2 and 1.5 moles of NADPH are consumed per mole of NO formed 
33
. 
NO BASED CELL SIGNALING: 
 cGMP dependent signalling  
NO diffuses into the nearby target cells to interact with specific molecular 
targets. NO regulates protein activity by reversibly binding to the accessible 
acceptor functionalities, including heme iron and thiols 
34
. The interaction between 
NO and the enzyme guanylyl cyclase, which mediates target cell responses such as 
vascular smooth muscle relaxation and platelet inhibition, has been well 
characterized 
35
. After entering the target cell, NO binds to the heme moiety of 
guaynylyl cyclase and activates the enzyme by inducing a conformational reorder 
that displaces iron out of the plane of the phorphoryrin ring 
36
. Guanylyl cyclase 
then catalyzes the production of cyclic GMP from GTP to evaluate cyclic GMP, 
which activates a cascade of intracellular events that brings about a reduction in 
calcium-dependent vascular smooth muscle tone, by inactivating myosine light 
chain kinase (MLCK)
37
. MLCK normally phosphorylates the regulatory set of 
myosin light chains. This event activates cross-bridge cycling and initiates 
14 
 
contraction 
38
. cGMP modulates MLCK activity by activating a cGMP – dependent 
protein kinase that phosphorylates MLCK. Phosphorylation of MLCK diminishes 
its affinity for calmodulin and, as a consequence, decreases the phosphorylation of 
myosin light chain, which in revolve stabilizes the idleform of myosin. In this 
manner, cGMP may induce vasorelaxation by indirectly decreasing myosin light 
chain - dependent myosin activation. 
GUANYLYL CYCLASE: 
Soluble GC(sGC) is a heme - containing, heterodimeric NO receptor. sGC 
consists of two subunits, which makeup the active enzyme. sGC isoforms, products 
of four genes, have been identified so far as . Only and heterodimers are activated 
by NO 
39
. The sGC is the most large iso form 
40
. Vascular smooth muscle and 
endothelial cells indicate predominantly subunit
41
. The functional importance of 
sGC was demonstrated by the significantly decreased relaxing effects of major 
vasodilators such as acetylcholine, NO, YC – 1 and BAY 41 – 2272 in the sGC 
knockout mice 
42
. 
Through the production of cGMP, sGC can exert many physiological results 
such as mediating vascular smooth muscle tone and motility, phototransduction, 
and maintaining fluid and electrolyte hemeostasis 
43
. The sGC activity increases 
more than 200 fold in response to NO 
44
. This signal is quickly removed by the 
action of phosphodiesterase 5A enzyme. 
15 
 
SPLICE FORMS AS NOVEL GENETIC REGULATORS OF sGC: 
Recently, the necessary importance of sGC for mammalian physiology was 
directly confirmed by generation of sGC knockout mice 
45
. The absence sGC 
protein resulted in a significant increase in blood pressure, complete loss of NO - 
dependent aortic relaxation and platelet aggregation in knockout animals, which 
died prematurely at the age of 4 weeks due to severe gastrointestinal disorder 
46
. 
sGC function is affected not only by NO, but also by the regulation of the 
expression of sGC subunits at transcriptional levels. The steady state mRNA levels 
of subunits decrease with hypertension, ageing and vary during embryonic 
development 
47
. The expression of sGC subunits is regulated by estrogen, cAMP – 
elevating compounds, cytokines and NO donors. Gene therapy with subunits may 
provide future therapeutic utility in hypertension. 
ALLOSTERIC EFFE CTORS OF sGC: 
There are many allosteric regulators of sGC which provide NO independent 
activation. Compounds that activate sGC in an NO – independent manner might 
therefore provide considerable therapeutic advantages 
48
. NO -  independent but 
heme -  dependent stimulators of sGC are YC – 1, BAY 41 – 2272, BAY 41 – 
8543, A-350619 and CFM-1571. NO as well as heme – independent sGC 
activators are BAY 58 – 2667 and HMR- 1766. 
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cGMP INDEPENDENT SIGNALLING: 
Nitrite and Nitrate: 
Nitrite is an oxidative breakdown product of NO that has been shown to 
serve as an acute marker of NO formation 
49
. Nitrite has recently moved to the 
forefront of NO biology 
50
 as, it represents an important storage from of NO in 
blood and tissues 
51
. Much of the recent focus on nitrite physiology is due to its 
ability to be reduced to NO
52
, during ischemic or hypoxic events 
53
. They get 
converted to NO and exert their physiological events. Evidences for this include: 
 Enriching dietary intake of nitrite and nitrate translates into significantly less 
injury from heart attack 
54
. 
 Nitrite therapy given intravenously prior to reperfusion protects against 
myocardial injury 
55
 and cerebral vasospasm 
56
. 
 Inhalation of nitrite selectively dilates the pulmonary circulation under 
hypoxicconditions in vivo in sheep 
57
. 
 Topical application of nitrite improves skin infections and ulcerations 58.  
 Oral nitrite has also been shown to reverse L-Nitro Arginine Methyl Ester (L-
NAME) induced hypertension and serve as an alternate source of NO in vivo 
59
. 
 Plasma nitrite levels progressively decrease with increasing cardiovascular risk 60. 
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In addition to the oxidation of NO, nitrite is also obtained from reduction of 
salivary nitrite by commensal bacteria in the mouth and gastrointestinal tract 
61
 as 
well as from nitrite rich diet. Since a substantial portion of nitrite in blood and 
tissue are derived from dietary sources
62
, modulation of nitrite and/or nitrate intake 
may provide the first line of defense for conditions associated with NO 
insufficiency.  
The primary dietary sources of nitrates and nitrites comprises plants, 
vegetables and few fruits, nuts, processed and cured meat, fish and poultry and 
drinking water, to which nitrites have been added. Plant foods are the primary 
sources of nitrate, while processed and cured meats are the primary sources of 
nitrites 
63
. 
       Since the NO radical is rapidly metabolized into the stable end-products, 
nitrite and nitrate. Determination of nitrite and nitrate does not demonstrate 
ongoing NO production. Considering that the half-life of nitrate in plasma is 5h 
64
, 
increased concentrations of nitrate in plasma after overnight fasting indicate recent 
NO production. The most commonly used nitrite and nitrite assay is based on the 
Griess diazotization reaction, which is specific for nitrite and does not detect 
nitrate. Therefore nitrate in samples must first be reduced to nitrite; subsequent 
nitrite determination thus yields the total nitrite + nitrate concentration of the 
sample (NOx). 
18 
 
 
Various study on plasma NOx assay: 
(a) Recovery of nitrite and nitrate from plasma is near quantitative (87%) and 
reproducible. 
      (b) Nitrite and nitrate are stable in (frozen) plasma for at least 1 year. 
      (c) Nitrite in whole blood is very quickly (>95% in 1 h) oxidized to nitrate, and 
therefore plasma nitrite determination alone is unmeaning, 
      (d) Plasma nitrite and nitrate concentrations were not correlated (nitrite as % of 
total nitrite + nitrate varied from 3.9% to 88% in plasma samples). 
      (e) Plasma samples should be de-proteinized, and background controls should 
be included in the assay, to avoid measuring the falsely high nitrite and nitrate 
concentrations in plasma. 
 
S-NITROSOTHIOLS: 
      S-nitrosothiols are thio-esters of nitrite, with the general structure R-S-N=O; 
naturally occurring examples include S-nitrosocysteine, S-nitrosoglutathione and 
nitrosoalbumin, in which R is an amino acid, polypeptide and protein respectively. 
Reactive protein thiols are regarded as crutial intracellular target of NO. Nitrite is 
in steady state of equilibrium with S-nitrosothiols.  
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S-nitrosation has since been involved in the control of a broad array of 
protein functions and cell activities like, regulation of apoptosis, G-protein-coupled 
receptor based signalling, vascular tone and inflammatory responses 
65
.  Among 
the growing list of proteins whose activities are regulated by s-nitrosation some 
are, ion channel proteins, kinases, proteolytic enzymes, transcription factors and 
proteins involved in energy transduction 
66
.  Dysregulation of protein S-nitrosation 
is associated with a growing list of pathophysiological conditions and altered blood 
levels of RSNO have been associated with impaired clinical outcome in patients 
with cardiovascular disease 
67
. 
S-nitrosoglutathione reductase (GSNOR), a member of alcohol 
dehydrogenase family, has been shown to be the primary pathway through which 
cells denitrosate intracellular proteins 
68
. GSNOR has become an important target 
for developing agents that modulate NO bioactivity inside the cells. 
NITROTRYOSINE: 
NO reacts with superoxide anion to form peroxynitrite, that can further form 
peroxynitrous acid, a very unstable and reactive oxidizing species. Action of 
ONOO
-
 is the most widely studied mechanism of protein nitration
69
. The formation 
of nitrotyrosine has been detected in various pathological conditions including 
atherosclerosis, myocardial infarction, hypertension, myocarditis heart failure, 
shock, diabetic complication and neurodegenerative and inflammatory disorders 
70
. 
  
 
Figure 3: 
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Substantial evidence has emerged which reveal a very close association 
between the formation of nitro-tyrosine and the presence of activated granulocytes 
containing peroxidases, such as MPO 
71
. MPO-generated reactive species 
participate in the induction of foam cell formation, endothelial dysfunction and 
development of plaque. Carr and Frei have revealed that, physiological 
concentrations of nitrite inhibit MPO mediated modification of LDL 
72
 providing a 
means to interrupt the process. These data also demonstrate the first line of 
evidence of nitrite acting as an “antioxidant” in atheroscleorosis. This may 
represent a novel mechanism by which metabolites of NO may exert an anti-
atherogenic effect.  
NITRIC OXIDE SYNTHASES: 
         The NOSs were first identified and described in 1989. The three major 
isoforms were cloned and purified between 1991 and 1994. The first X-ray crystal 
structures of NOS domains have been presented and published in 1998 and 1999. 
         Three quiet distinct isoforms of NOS have been identified as products of 
different genes, with different localization, regulation, catalytic properties, and 
inhibitor sensitivity, and with 51-57% homology between the human isoforms. 
These isoforms will be referred to, by the most common nomenclature, based on 
the order in which they were first purified and cloned. 
  
 
Figure 4: 
Regulation of Endothelial Nitric Oxide Synthase 
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nNOS (also known as Type 1, NOS-1 and NOS-1) being the isoform first 
found (predominating) in neuronal tissue. 
iNOS (also known as Type 2, NOS-11 and NOS-2) being the isoform which 
is inducible in a wide range of cells and tissues. 
eNOS (also known as Type 3, NOS-111 and NOS-3) being the isoform first 
found in vascular endothelial cells. 
        In the past, these isoforms have also been differentiated on the basis of their 
constitutive (eNOS and nNOS) versus inducible (iNOS) expression and their 
calcium – dependence (eNOS and nNOS) or independence (iNOS). 
STRUCTURE:  
            NOS exhibits a bi-domain structure, in which an N-terminal oxygenase 
domain containing binding sites for heme, BH4 and L-arginine, is linked by a 
calmodulin-recognition site to a C-terminal reductase domain, containing binding 
sites for FAD, FMN and NADPH
73.
. The known NOS enzymes are usually referred 
to as „dimeric‟ in their active form, ignoring the required calmodulins (CaMs) 
which, strictly speaking, mean they are tetramers (of two NOS monomers 
associated with two CaMs). They contain relatively tightly bound cofactors BH4, 
FAD, FMN and heme. 
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NOS dimerization: 
The association of the NOS into active dimers, involves a large interface in 
the oxygenase domain, involving two sections of the primary structure of NOS
74
. 
This interface includes the binding site for BH4 and helps to structure the active-
site pocket containing the heme and the L-arginine binding site; it has two cysteine 
residues per monomer, which either forms a disulphide bridge between the 
monomers or ligates a zinc ion between the monomers
75
. Furthermore, there is an 
„N-terminal hook domain‟, which swaps between the two monomers, to stabilize 
the dimer
76
. BH4 as well as heme and L-arginine promote and stabilize the active 
dimeric form of all the three isoforms.  
The presence of heme appears to be mandatory, with BH4 and L-arginine 
promoting dimer formation and stabilization. The flow of electrons from reductase 
domain of one monomer, to the oxygenase domain of the other monomer forms 
NO. 
Endothelial cell constitutive nitric oxide synthase can be activated by stimuli 
that include thrombin, adenosine, bradykinin, substance P, muscarinic agonists, 
catecholamines and shear stress
77
.  
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REGULATION OF NOS:  
CALMODULIN: 
              Calmodulin was the first protein shown to interact with NOS and is 
necessary for the enzymatic activity of the three isoforms. CaM binding increases 
the rate of electron transfer from the reductase domain to the heme centre
78
. 
PHOSPHORYLATION:  
              Phosphorylation of the nNOS and eNOS isoforms has an effect on NOS 
activity. Fluid shear stress elicits phosphorylation of eNOS and an increase in its 
activity
79
.  
HEAT-SHOCK PROTEIN 90(hsp90): 
The molecular chaperone hsp90 has been identified as a regulator of eNOS 
activity, possibly as an allosteric modulator
80
. Activation by vascular endothelial 
growth factor, histamine or fluid shear stess in human endothelial cells increases 
the interaction between eNOS and hsp90andincreaseseNOSactivity by 
approximately three-folds. Kallikrein appears to inhibit iNOS by preventing the 
formation of iNOS dimers
81
 and may play a neuroprotective role during 
inflammation. 
 
 
 
  
 
Figure 5:  
REGULATION OF eNOS LOCALIZATION – MYRISTOYLATION & 
PALMYTOYLATION  
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REGULATION OF eNOS LOCALISATION: 
MYRISTOYLATION and PALMITOYLATION: 
           Of the three NOS isoforms, only eNOS is acylated by both myristate and 
palmitate
82
.  eNOS is co-translationally and irreversibly myristoylated at an N-
terminal glycine residue while palmitoylation occurs post-translationally and 
reversibly at cysteine residues Dual acylation of eNOS is required for efficient 
localization to the plasmalemmal caveolae of endothelial cells
83
. Palmitoylation
84
 
is dynamically regulated by bradykinin – induced changes in intracellular Ca2+. 
CAVEOLIN: 
eNOS is localised to the caveolae
85
, which are microdomains of the 
plasmalemmal membrane that are involved in a variety of cellular functions 
including signal transduction events. Vascular eNOS binds to caveolin-1, while in 
cardiac myocytes, eNOS is associated with caveolin-3
86
. Caveolin-1 and peptides 
from the „caveolin-1 scaffold region‟ directly inhibit eNOS activity and this 
interaction is reversed by Ca
2+
/CaM
87
.Caveolin-3 binds to nNOS in the skeletal 
muscle, inhibiting NO synthesis and this inhibition is reversed by Ca
2+
/CaM
88
. 
PHYSIOLOGICAL ROLE OF NOS: 
Both eNOS and nNOS are constitutively expressed and are thought to 
contribute to the normal regulation of vasomotor tone and blood pressure
89
. eNOS 
derived NO was considered to be the most important regulator of vasomotor tone
90. 
  
Figure 6: 
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eNOS AND VASOMOTOR TONE: 
In the vascular endothelium, agonists such as acetylcholine and bradykinin 
stimulate inositol 1,4,5-triphosphate (IP3) production the second messenger system. 
IP3 binds to receptors on the endoplasmic reticulum and causes Ca
2+
 release from 
intracellular stores
91
.  
This transient elevation of intracellular Ca
2+
 promotes calcium binding to 
calmodulin, forming a complex that is a crucial cofactor for constitutive NOS 
activity
92
.  
eNOS GENE: 
Given the pivotal role of eNOS in vascular homeostasis, the eNOS gene 
(NOS3) has emerged as a logical candidate gene in the investigation of 
hypertension genetics
93
.   
This down regulation of eNOS mRNA, undoubtedly, contributes to the 
reduced endothelial NO production and defective endothelium- dependant vaso 
relaxation
94
 observed in diseased atherosclerotic vessel. It is now appreciated that 
decreased endothelial eNOS mRNA and protein can be observed in diseased 
human blood vessels. 
NOS3 gene is located in the chromosome 7, corresponding to the 7q35-q36 
region, contains 26 exons with an entire length of 21kb. 
 
 Figure 7: 
REGULATION OF eNOS GENE EXPRESSION: 
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REGULATION OF eNOS GENE EXPRESSION: 
Numerous exogenous stimuli and condition that are relevant to the 
pathology of vascular endothelium have been shown to alter eNOS expression 
through the modulation of steady-state eNOS mRNA
95
. This regulation happens at 
both the transcriptional and posttranscriptional levels. 
TRANSCRIPTIONAL REGULATION: 
eNOS CORE PROMOTER: 
The eNOS gene encodes a mRNA of 4052 nucleotides and is present as a 
single copy in the haploid human genome. Sequence inspection of 5‟-flanking 
regions revealed multiple potential cis-regulatory DNA sequences in the setting of 
a “TATA-less” promoter: Sp1, GATA, AP-1, NF-1, shear-stress response 
elements, and sterol-regulatory elements
96
. There are two tightly clustered cis-
positive regulatory elements in the proximal promoter of the human eNOS gene.  
Positive regulatory domain 1(PRD 1- 104 to -95 relating to transcription 
initiation) was mapped to a 10-bp cis-region corresponding to a high affinity Sp1 
transcription factor recognition site. PRD 11 (-144 to -115) encompassed a 30-bp 
region of the core promoter and formed nucleoprotein complexes containing the 
transcription factors Elf-1, YY1,Spl and MAZ
185
. Mutating cis-elements in PRD 1 
or PRD11 disrupted co-operative activation of the human promoter
97
. 
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CELL SPECIFIC EXPRESSION: 
eNOS gene expression is relatively restricted to the vascular endothelium. 
The existence of a distal enhancer element has the ability to direct the appropriate 
cell-specific expression pattern of the eNOS gene. The human eNOS proximal 
promoter was differentially methylated in expressing and non-expressing cell 
types
98
. In non-expressing cells, the core promoter CpG di-nucleotides were 
densely methylated, whereas in eNOS-expressing endothelial cells they were non-
methylated. Differential promoter methylation was further implicated in the 
determination of cell-specific eNOS expression, by the successful induction of 
endogenous eNOS mRNA expression in non-expressing cell types. This may occur 
in response to de-methylation by 5-azacytidine, a DNA methyltransferase inhibitor. 
It has been suggested that promoter methylation down regulates transcription by 
recruitment of methyl-CpG binding proteins and histone de-acetylase activity, 
resulted in a close and transcriptionally repressive chromatin structure
99
. 
POST TRANSCRIPTIONAL REGULATION: 
TUMOR NECROSING FACTOR (TNF): 
  TNF has been shown to decrease endothelium-dependant vaso-relaxation in 
vivo and ex vivo
100
.  Some of the studies of eNOS gene regulation, identified 
modulation of mRNA stability as a regulatory target of pro-inflammatory 
cytokines
101
. Indeed, TNF the half- life of eNOS mRNA from 48 hours to 3 
hours
102
. 
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DUAL REGULATION: 
TRANSCRIPTIONAL AND POSTTRANSCRIPTIONAL EFFECTS: 
OXIDIZED LOW DENSITY LIPOPROTEINS: 
Liao et al first reported that, oxidized low density lipoproteins (ox-LDL) 
caused a time and concentration-dependant decrease in steady-state eNOS mRNA 
and enzyme activity in human endothelial cells
103
. This down- regulation was 
found to occur principally at the post-transcriptional level, resulting in a reduction 
in eNOS mRNA half-life from 36 to 10 hours. Low concentrations are ox-LDL 
(≤10µg protein/ml) may be associated with a paradoxical increase in eNOS mRNA 
and protein expression
104
. Very high levels of native LDL were found to decrease 
eNOS mRNA expression
105
. Lysophosphatidyl choline a major component of ox-
LDL, can increase eNOS mRNA in BAEC. Perhaps this provides a clarification for 
the biphasic effect of varying doses of ox-LDL. 
eNOS GENE POLYMORPHISM: 
            Variants of the NOS3 gene located in the 7q35-q36 regions, contains 26 
exons with an entire length of 21kb have been investigated for association with 
hypertension and other cardiovascular disorders. Of these, three polymorphisms 
have been broadly examined for clinical relevance, based on their potential 
functional effects and their relatively high minor allele frequency in various ethnic 
groups
106.
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(1) a G894T substitution in exon7 resulting in a Glu to Asp substitution at codon 
298 (rs1799983). 
(2) an insertion deletion in intron4 (4a/b) consisting of two alleles (the a-deletion 
which has four tandem 27-bp repeats and the b-insertion having five repeats). 
(3) a T786C substitution in the promoter region (rs2070744). 
Several polymorphisms of eNOS gene are found to be associated with 
increased risk for cardiovascular disease. Of these 894 G greater than T variant in 
exon 7 is reported to be associated with cardiovascular disease 
107
 while 786 T 
greater than C polymorphism has been associated with hypertension and with 
coronary spasm. The transition markedly blunts the transcription of eNOS Gene 
and hence the nitric oxide production. The C allele creates the binding site for 
replication protein A1 (RPA1) that‟s acts as a suppressor for eNOS transcription. 
The transition markedly blunts the transcription of eNOS gene and hence the nitric 
oxide production. Replication protein A1 resides in endothelial cells and placenta.  
Hence Preeclampsia women are associated with a high frequency of promoter T-
786C polymorphism presents with low serum levels of Nitric oxide. 
The endothelial NOS isoform appears to be localized in the resistance 
vasculature of the placenta, but not in the capillary endothelium of terminal villi 
where there is no underlying smooth muscle. The pattern of staining with NBT is 
similar to that of endothelial NOS and suggests that other isoforms of NOS are not 
present in the placental unit
108
.  
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A gene polymorphism is defined as the regular occurrence (>1%) in a 
population of two or more alleles at a particular chromosome location. For 
promoter -786 T>C polymorphism, the wild-type allele (-786T allele) is uncut 
upon Msp I digestion and is detected as a 178- bp band, whereas the polymorphic 
allele (-786C allele) is cut into two fragments detected as a 137- and a 41-bp 
bands.  Therefore, wild-type homozygous individuals should generate a single 178-
bp product, heterozygous individuals should generate three fragments 178,137-and 
a 41-bp, while mutant homozygous individuals should generate a two; 137- and a 
41-bp fragments
109
.  
Nitric oxide (NO) is a potent vasodilator, considered to have major effects 
on gestational endothelial function
110
. NO is synthesized by nitric oxide synthases 
(NOS), namely endothelial NOS (eNOS), inducible NOS (iNOS), and neuronal 
NOS
111
. Studies investigating circulating levels of NO in preeclampsia have 
reported conflicting results
112
. This is in contrast to studies that have shown that 
plasma from women with preeclampsia elicits reduced endothelium-dependent 
vasodilatation in isolated vessels. NO availability may be decreased
113.
because of 
oxidative stress, vascular endothelial growth factor deficiency, or endogenous 
inhibitors, such as asymmetric dimethylarginine
114
. It is assumed that most of the 
circulating NO derives from maternal endothelium. But, the placenta may also 
contribute. 
31 
 
 
In the placenta, NOS is predominantly expressed in the syncytiotrophoblast, 
villous endothelium, and macrophages; the predominant isoform being eNOS
115
. 
The multinucleated syncytiotrophoblast layer lining the chorionic villi is the 
interface between the maternal and fetal vascular systems
116 
and could contribute to 
circulating NO. 
 
The gene for eNOS is located on chromosome 7 (7q35-q36), as a single 
copy of 26 exons with an entire length of 21 kb, and encodes an mRNA of 4052 
nucleotides 
117
. Disruption of the eNOS gene leads to hypertension in mice 
118
 and 
inhibition elevates blood pressure in healthy humans. eNOS is a constitutively 
expressed isoform whose activity is dependent on the intracellular changes in Ca2+ 
concentrations. eNOS expressed in the terminal villous vessels in the 
syncytiotrophoblast is the main enzyme required for vascular NO production and 
influences placental human chorionic gonadotrophin production during gestation. 
Trophoblast cells in the first trimester express high amounts of eNOS 
119
. Studies 
undertaken to find  eNOS gene variations have revealed that many cis- and trans-
acting factors regulate the expression of eNOS and that its expression level in turn 
directly corresponds to the amount of NO in the blood 
120
.  
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It has been shown that polymorphisms in the coding and non-coding regions 
of eNOS may alter eNOS expression and/or activity and thus cause a decrease in 
NO synthesis 
121
, which may predispose patients to hypertension, vasospasm and 
atherosclerosis, renal failure and pre-eclampsia
122
. 
Nitric oxide (NO) plays a major role in vascular homeostasis. Produced in 
endothelial cells and platelets by endothelial NO synthase (eNOS) 
123
, NO 
mediates vascular dilation, inhibits platelet aggregation, posttranslational protein 
modification, cell migration and angiogenesis, and apoptosis 
124
. Indeed, reduced 
bioavailability of NO has been linked to numerous important cardiovascular 
pathological processes 
125
 and there is now evidence of a genetic contribution to the 
variability in NO formation 
126
. Due to the relevance of NO in the regulation of the 
cardiovascular system, eNOS gene polymorphisms have been associated with 
cardiovascular diseases 
127
. 
The endothelial nitric oxide synthase (eNOS) gene has been enlisted by 
previous research as a candidate gene of preeclampsia predisposition. This study 
investigates the specific roles of 3 polymorphisms of the eNOS gene in a 
population of Chinese origin from mainland China. The 3 commonly studied 
polymorphisms of the eNOS gene, namely 4b/a, T786C and Glu298Asp, in a case-
controlled sample of 220 patients diagnosed with preeclampsia and 200 healthy 
controls. The association between eNOS polymorphisms and preeclampsia was 
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evaluated by performing genotyping for the eNOS variants and calculating odds 
ratios (OR) and 95% confidence intervals. The plasma nitrite concentration in 
participants was determined to examine how 3 eNOS polymorphisms affect plasma 
nitric oxide (NO) concentrations in pregnant women. Polymorphisms of the 
Endothelial Nitric Oxide Synthase Gene in Preeclampsia in a Han Chinese 
Population
128
.  As a potent vasodilator, circulating nitric oxide (NO) plays a crucial 
role in endothelial function regulation, blood pressure control, and cardiovascular 
homeostasis, and NO is essential for a predisposition to preeclampsia.  
NO has been shown in vitro and in vivo to modulate placental circulations, 
and the inhibition of NO production has caused preeclampsia-like syndromes in 
pregnant rats. Endothelial nitric oxide synthase (eNOS) is an enzyme which 
synthesizes NO constitutively via catalyzing the conversion of L-arginine to L-
citrulline. Because endothelial NO availability is largely regulated by its synthesis 
by eNOS, the gene that encodes eNOS, NOS3, is considered as a candidate gene 
for preeclampsia.  Three NOS3 polymorphisms have been extensively studied: 
G894T (a guanine/thymine substitution at position 894 on exon 7 leading to a 
change from glutamate to aspartate at position 298; rs1799983); T-786C mutation 
(a thymine/cytosine substitution at position 786 in the 5‟-flanking region of 
promoter; rs2070744); and a variable number of tandem repeats (VNTR) 4b/a 
polymorphism [the a* -deletion allele with 27 bp VNTR in intron 4 129. 
  
 
 
AIMS AND          
OBJECTIVES 
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AIM & OBJECTIVES 
AIM OF THE STUDY: 
• To find an association between eNOS gene polymorphism and                  
preeclampsia. 
OBJECTIVES: 
• To find out the distribution of allelic variant in promoter T-786C of eNOS 
gene in our population. 
• To look for any association between gene polymorphism and Preeclampsia. 
• To assess the Nitric oxide level in study group. 
• To correlate Nitric oxide level with eNOS gene polymorphism. 
 
 
 
 
 
  
 
 
 
 
 
 
MATERIALS AND 
METHODS 
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MATERIALS AND METHODS 
STUDY DESIGN            : CASE-CONTROL STUDY 
PLACE OF STUDY : Department of Biochemistry, 
      Department of Obstetrics and Gynaecology, 
      Govt.Kilpauk medical college, 
      Chennai – 10 
DURATION OF STUDY: 6 Months  
SAMPLE SIZE    : 100  
SAMPLE SELECTION:   
Cases: 50 Preeclampsia women in the age group of 20-40 years. 
Controls: 50 healthy pregnancy women. 
(Age and Risk Factor matched). 
No history or clinical evidence suggestive of Preeclampsia. 
Confidence interval is taken at 95% 
Power of the study: 75% 
Ratio of cases and controls: 1:1 
Prevalence of the disease: 8 %  
INCLUSION CRITERIA:  
Pregnant women age group of 20-40 years. 
Gestational age of 24 to 36 weeks of pregnancy. 
36 
 
Blood pressure higher than 140/90 mmHg on two occasions more than 6hrs apart 
and proteinuria.300mg/24hrs, after the 20th week of pregnancy. 
EXCLUSION CRITERIA 
• Smokers 
•  Renal disease 
•  Chronic illness 
•  Diabetes mellitus 
•  Systemic hypertension 
•  Acute/Chronic infection 
•  Ischaemic stroke &Coronary artery disease  
•  Fever 
•  Previous H/O Recurrent pregnancy loss 
•  Previous H/O  preeclampsia  
•  Anti Phospholipid Antibody Syndrome 
•  Multiple pregnancy 
•  Hypothyroidism 
SAMPLE COLLECTION:  
5 ml of Fasting venous blood sample: Collected in 2 tubes. 2ml in anticoagulant (1 
part of 5 % EDTA for each parts of blood) and 3 ml in plane tube and mixed by 
gentle shaking.  Whole blood used for DNA extraction and serum used for 
biochemical analysis. 
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Investigations: 
The following investigations are to be done in Cobas C311 auto analyser: 
1. Blood sugar – Hexokinase method  
2. Urea – GLDH Method  
3. Creatinine –Jaffe‟s Method  
4. Uric Acid – Modified Trinder Method  
5. Serum Nitric Oxide – Cadmium based reduction of nitrate to nitrate followed by 
griess Method 
6. Urine Microprotein – TCA Method  
7. Serum Calcium – Ortho-cresolphthalein Complexone Method 
8. Genetic Polymorphic studies includes 
I. DNA EXTRACTION: 
 Double-Stranded DNA will be isolated from human body by lysis of 
leukocytes with Subsequent selective DNA precipitation with detergent. 
 This DNA is concentrated and desalted by ethanol precipitation. 
 Purity of DNA is to be ascertained by calculating the A260/A280 ratio. 
II. GENOMIC DNA AMPLIFICATION BY PCR: 
Using primers flanking the polymorphic region of the eNOS gene. 
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III. 2 % AGAROSE GEL RUN: 
Following PCR, the presence of a 365bp Product will be ascertained by 
using 2 % agarose gel .Where it is visualized as a discrete band using a gel 
documentation system. 
 
DNA EXTRACTION BY KIT METHOD: 
DNA MINIPREPARATION KIT: 
From helini biomolecules, Chennai. 
PRINCIPLE : 
On short incubation with proteinase K and in the presence of chaotropic salt, 
cells are lysed which immediately inactivates all nucleases. Nucleic acids in the 
cells, attach selectively to special glass fibres pre-packed in the Purefast 
purification filter tube. In a series of rapid 'wash and spin‟ steps it removes the 
contaminating cellular components, thus bound nucleic acids get purified. A 
special inhibitor removal buffer was added, this allows even the application of 
heparinised sample material with 100U/ml of heparin. Finally low salt elution 
buffer releases the nucleic acids from the glass fibre. This method eliminates the 
need for organic solvent extractions and DNA precipitation, allowing for rapid 
purification of many samples simultaneously. 
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COMPONENTS OF THE KIT 
 Proteinase K solution 
 Lysis buffer 
 Wash buffer 1 & 2 
 Isopropranolol 
 Elution buffer 
 Spin columns with collection tubes 
PROTEINASE K SOLUTION STORAGE: 
Solution were stored at -20 °C. It is stable for at -20°C for upto 6 months. 
 
PROCEDURE FOR DNA PURIFICATION: 
PRE-PROCEDURE STEPS: 
 Set water bath to 56°C 
 Warm elution buffer by keeping in water bath at 56°C 
 Prepare fresh 1.2 ml of 70% ethanol per sample. 
BLOOD / BUFFYCOAT: 
200µl of blood or 200µl of buffy coat is added to a nuclease free 1.5ml 
microcentrifuge tube and the following steps are carried out. 
1. 400µl of  lysis buffer is added and 
2. Immediately mixed well by inverting several times (or gently vortex) 
3. 20µl of proteinase K was added. 
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4. Mixed by vortex for 10 seconds. 
5. 300µl of isoproponalol was added and mixed well by inverting several 
times. 
6. The sample was pipetted into the Purefast spin column and 
7. Centrifuged at 12,000rpm for 1min. 
8. The flow-through was discarded and the column is positioned back into the 
same collection tube. 
9. 500µl of Wash buffer I was added to the Purefast spin column and 
10. Centrifugation process for 1minute at 12,000 rpm and the flow-through is 
discarded and the column was placed back into the same collection tube. 
11. 500µl wash buffer II was added to the Purefast spin column. 
12. Centrifuged at 12,000rpm for one minute and the flow-through discarded 
the column was placed back into the same collection tube. 
13. Do empty spin column centrifuge at 13000rpm for 2 minutes. 
14. The flow-through was discarded and centrifuged for an additional. This 
step was essential to avoid residual ethanol. 
15. The Purefast spin column is transferred into a fresh 1.5 ml microcentrifuge 
tube. 
16. 60µl of the pre-warmed elution buffer was added to the centre of Purefast 
spin column membrane.  
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17. Take care not to contact the membrane with the pipette tip. Incubation pre 
warmed was done at room temperature for two minutes and is centrifuged 
for two minutes. 
18. The column was discarded and the purified DNA was deep freezed at -
20°C. 
IDENTIFICATION 
Extracted DNA was identified by 1% agarose gel electrophoresis and 
comparison with a known molecular weight 1kb DNA (Lambda DNA) ladder. 
POLYMERASE CHAIN REACTION 
HELINI  rs 2070774 [C>T ] Human  SNP Genotyping PCR Kit 
Kit components  
No.of Reactions 50 tests 
Red dye PCR Master Mix - 10µl/reaction 500 µl 
Rs2010963 Primer Mix – 2.5µl/reaction  125 µl 
PCR grade water 4 ml  
 
C allele: PCR product size: 365 bp C 
T allele: PCR Product size: 211 bp T 
Control PCR Product size: 576 bp Control 
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C allele: 
F:CCTCCACTGCTTTTCAGAGG 
R:CTGAGGCAGGGTCAGACG 
365bp 
 
T allele: 
F:CATCAAGCTCTTCCCTGTCT 
R:TGACATTAGGGTATCCCTTCC 
211bp 
 
PRIMER RECONSTITUTION 
Primers were supplied in lyophilized form. Millipore double distilled water 
was used to prepare 100× concentrations i.e. 10 times the molecular weight of 
primer is the volume of water required to prepare 100× concentrations which is 
100µmolar solution. 
From this stock solution 10× concentration  was prepared as the working solution 
for PCR. 
Both forward and reverse primer were spinned. 
For each polymorphic site TEA buffer was taken at a particular volume 
corresponding to the respective forward & reverse primer of 100 pmol/µl. 
Inverted & Vortexed &mixed for 5 minutes & were centrifuged 
Eppendorf  were named for the polymorphic sites. 
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180 µl of sterile distilled water were taken in the labelled Eppendorf. 
10 µl forward primer + 10 µl reverse primer were added 
200 µl of reconstituted primers containing both forward and reverse primers for the 
respective polymorphic sites. 
MASTER MIX:  
2×PCR Master mix was used in the following composition 
Master Mix consists of basic components necessary for PCR. 
Reaction buffer consisted of Tris Hcl - pH 8.5, (NH4)2SO4, MgCl2 – 3 mM acts as 
catalyst & 0.2% Tween 20. 
dNTP‟ s were used in a concentration of 0.4 mM each. 
Taq polymerase in a concentration of 0.2 U/ µl. 
Primers were used in a concentration of 10 pmol and DNA was used in a 
concentration of 200ng. 
PCR was carried out in a reaction in volume of 20µL with the following 
components in the following manner, 
PCR master mix (contains gel loading dye)  – 10 µL 
Reconstituted  primers (for the site+83) – 5.0 µL 
DNA       – 5.0µL 
----------------- 
Total       -  20.0µL 
----------------- 
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POLYMERASE CHAIN REACTION (PCR) 
Amplification of the extracted DNA was carried out in CYBERLAB 
SMART PCR-PRO, thermal cycler with the following cycling conditions. 
 
Negative Control 
Use 7.5µl of nuclease free water  
Centrifuge PCR vials briefly before placing before into thermal cycler. 
 
STEPS INC-786T (PROMOTER) OF NITRIC OXIDE SYNTHASE GENE 
PCR POLYMORPHIC SITE: 
 Initial denaturation -  95° C /5min 
34cycles of 
 Cycle Denaturation at 94°C for  30 seconds 
 Cycle Annealing  at 58°C  for 30 seconds 
 Cycle Extension at 72°C  for 30 seconds 
 Final Extension at 72°C for 10min 
Amplified product–amplicons of 365 bp was identified by 2.5% agarose gel 
electrophoresis by comparison with a known 100bp DNA ladder. 
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AGAROSE GEL ELECTROPHORESIS 
 Agarose gel preparation 
 Gel casting 
 Sample preparation 
 Electrophoresis 
Material Required 
Micro centrifuge 
UV transilluminator (optional) (Cat.no.09-01) 
Mini submarine electrophoresis unit with power pack (Cat.No.03-01P) 
Micro oven or water bath 
Micropipettes & fresh tips (10µl - 200µl, 200µl-1000µl) 
Conical flask, ice bath or crushed ice 
Micro centrifuge tubes, measuring cylinder 
Distilled water 
Material Required 
Materials  15 Exp Storage 
Agarose  5 gm Room temperature 
50X TAE 100 ml  Room temperature 
6X gel loading dye  500µl  -20°C 
Ethidium bromide  100µl -20°C 
 
Figure 8: 
GEL DOCUMENTATION OF EXTRACTED DNA: 
 
Figure 9: 
ELECTROPHORETOGRAM OF PCR PRODUCTS 
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 PCR product was run on 2.5% agarose gel in a 25 ml agarose cast as follows: 
0.625g of agarose was weighed and dissolved in 25 ml of TAE buffer with a pH 
of 8.0. 
 It was microwaved for 60 secs, cooled and ethidium bromide was added in a 
concentration of 0.5 µg/ml from the stock of 10mg/ml added. It is poured into a 
cast and allowed to solidify for 45 min before it was kept in the electrophoresis 
tank. 
 10µL of PCR product was loaded onto wells and 4µL of 100bpDNA ladder was 
loaded onto single well as a marker. It is run in an electrophoresis tank for 
30min and visualized under UV illumination in e gel imager from life 
technologies. 
 C allele : PCR product size : 365 bp C 
  T allele: PCR Product size: 211 bp T 
   Control PCR Product size : 576 bp Control 
C ALLELE-PCR product size 365bp C 
T ALLELE-PCR product size 211bpT 
Control PCR Product size : 576 bp Control 
CC (homozygous individuals) - will yield 365bp, 576bp 
CT (heterozygous individuals) - will yield 365bp, 576bp, 211bp 
TT (homozygous individuals) - will yield 211bp, 576bp 
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MEASUREMENT OF SERUM NOx: 
CADMIUM BASED REDUCTION OF NITRATE TO NITRATE 
FOLLOWED BY GRIESS METHOD: 
Principle:  
In this method, cadmium, exposed to copper sulphate solution reduces Cu
2+ 
form a porous metallic copper “coat”. This copper facilities electron transfers from 
cadmium to nitrate, thereby reducing nitrate to nitrate.  Cadmium has a reduction 
potential of -0.403 V.  On the other hand, redox potential of nitrate/nitrate is 
dependent on pH ranging from 0.94 V in acidic solution to 0.015V in basic 
solution.  Therefore, reduction reaction of nitrate to nitrate by cadmium is 
thermodynamically favourable. 
 
Nitrate reacts with sulfanilamide in acidic media to form transient diazonium 
salt.  N-naphthyl-ethylenediamine (NED) converts this salt to a stable azo 
compound with intense purple color, measured at 540 nm. 
Procedure: 
Step 1: De-proteinisation: 
300 µl of serum by adding 250 µl of 75 mmol/L ZnSO4 solution, stirring, 
and centrifuging at 10000g for 1 minute at room temperature, after which 350 µl of 
55 mmol/L NaOH was added.   
 
  
 
Graph 1: 
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Again, the solution was stirred and centrifuged at 10,000g for 3 minutes and 
the supernatant was recovered (free of turbidity). Then diluted by mixing 750µl of 
supernatant with 250 µl of glycine buffer (45g/L, pH 9.7). 
Step 2:
 
Cadmium granules were rinsed three times, with deionized distilled water 
and mixed in a shaker gently in a 200 mmol/L copper sulfate
231
solution in glycine-
NaOH buffer (15 g/L, pH 9.7) for 5 minutes till the color of the solution fades.  
The solution was drained off and the step was repeated.  The copper-coated 
granules dried in tissue paper, should be used within 10 minutes.  After use, the 
granules were rinsed and stored in 100 mmol/L   H2SO4 solution: they can be 
regenerated by repeating the steps. 
Step 3: 
The nitrite and nitrate calibrators were diluted with glycine buffer. 
Calibration curves were made over a linear range of nitrite between 0 and 100 
umol/L.  Freshly activated cadmium granules (2-2.5g) were added to 1 ml of pre-
treated de-proteinized serum and calibrator.  After continuous stirring for 10 
minutes, the samples were transferred to appropriately labeled tubes for nitrate 
determination.   
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Step 4: Nitrite Assay: 
Nitrite was estimated by Griess method. 
Reagent 1:5 mg of N-naphthyl ethylenediamine dissolved in 250 ml of distilled 
water. 
Reagent 2: 5 g of sulfanilic acid in 500 ml of 3 mol/L HC1. 
Both solutions are stable for one year at 4 
o
C. 
 From the above tubes 200 µl of sample were placed into fresh glass tubes.  
Then 800 µl sulfanilic acid solution was mixed, followed by 750 µl  NED solution. 
After an incubation period of 10 minutes at temperature, pink color was 
developed and its absorbance read at 545 nm within 60 min.  The measured OD 
was plotted on the standardization graph and concentration found out.  (Graph: 1) 
Estimation of Glucose in Blood (Hexokinase Method).
 
Principle: 
    Hexokinase catalyzes the phosphorylation of glucose to glucose-6-phosphate by 
ATP. Glucose-6-phosphate dehydrogenase oxidizes glucose-6-phosphate in the 
presence of NADP to gluconate-6-phosphate. The rate of NADPH formation 
during the reaction is directly proportional to the glucose concentration and is 
measured photometrically. 
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Glucose + ATP --------------------˃ G-6-P + ADP 
 
G-6-P + NADP+-----------------------------------------------------˃ Gluconate-6-P + NADPH + H+ 
Reagents: 
R1 
 MES buffer: 5.0 mmol/L, pH 6 
 Mg2+: 24 mmol/L 
 ATP:> 4.5 mmol/L 
 NADP: > 7.0 mmol/L 
 Preservative 
R2 
 HEPES buffer: 200 mmol/L, pH 8.0 
 Mg2+: 4 mmol/L 
 HK (yeast): > 300 µkat/L 
 G-6-PDH (E. coli): > µkat/L 
 Preservative. 
Reagent preparation 
Reagent are provided ready to use. 
 
hexokinase 
Glucose 6 phosphate dehydrogenase 
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Procedure 
The assay was carried out using Cobas C311 autoanalyser. 
Reference Range 
Normal serum level: FBS: 70 – 109 mg/dl and PPBS – 80-139 mg/dl. 
Estimation of serum urea (Kinetic test with urease and glutamate 
dehydrogenase method) 
Principle: 
The urea is hydrolysed by urease to produce ammonia and carbonate. In the 
second reaction 2-oxoglutarate reacts with ammonium in the presence of glutamate 
dehydrogenase (GLDH) and the coenzyme NADH to produce L-glutamate. In this 
reaction two moles of NADH are oxidized to NAD+ for each mole of urea 
hydrolyzed. 
The rate of decrease in the NADH concentration is directly proportional to 
the urea concentration in the specimen and is measured photometrically. 
Urea + 2 H2O -------------˃2 NH4
+
 + CO3
2- 
NH4
+
 + 2-oxoglutarate + NADH -------------------------˃L-glutamate + NAD+ + H2O 
Reagent 
R1 
 NaCl 9% 
Urease 
Glutamate dehydrogenase 
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R2 
 TRIS buffer: 220 mmol/L, pH 8.6; 
 2-oxoglutarate: 73 mmol/L; 
 NADH: 2.5 mmol/L; 
 ADP: 6.5 mmol/L; 
 Urease (jack bean): > 300 µkat/L; 
 GLDH (bovine liver): > 80 µkat/L; 
 Preservative; 
 Nonreactive stabilizers 
Procedure 
The estimation was carried out by Cobas C 311 autoanalyser. 
Reference range 
Normal serum level: 15 – 40mg/dl. 
Estimation of serum Creatinine (Buffered Kinetic Jaffe’s Reaction without 
deproteinisation) 
Principle 
In alkaline solution creatinine reacts with picrate to form a yellow-red 
adduct. The rate of the dye formation (color intensity) is directly proportional to 
the creatinine concentration in the specimen and is measured photometrically. 
Creatinine + picric acid  --------˃ yellow-red complex. 
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Reagents 
R1 
 Potassium hydroxide: 900 mmol/L; 
 Phosphate: 135 mmol/L; pH> 13.5; 
 Preservative; 
 Stabilizer 
R2/R3 
 Picric acid: 38 mmol/L; pH 6.5; 
 Non reactive buffer 
Procedure 
The estimation was carried out using Cobas C 311 autoanalyser. 
Reference range 
Normal serum level: Men: 0.9-1.3mg/dl. 
Women:  0.6-1.1mg/dl. 
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ESTIMATION PF CALCIUM BY ORTHO-CRESOLPHTHALEIN 
COMPLEXONE METHOD (OCPC METHOD)
232 
Principle: 
Ortho-cresolphthalein reacts with calcium in alkaline solution to form a 
purple coloured complex.  The intensity of the purple colour formed is proportional 
to the calcium concentration and is measured photometrically at 578nm.  Interface 
from magnesium is overcome by the presence of 8-hydroxyl quinoline in reagent 2 
which binds free magnesium ions. 
Reagents:   
 Reagent 1: AMP Reagent 
2-Amino-2-methyl-1 propanol 505mmol/L 
Surfactant - 
 
Reagent 1: OCPC Reagent 
OCPC 0.06mmol/L 
8-Hydroxy Quinoline 6. 9 mmol/L 
HCl 45  mmol/L 
Surfactant       - 
 
 
55 
 
Calcium Standard: 
Calcium Standard 10.0mg/dl (2.5 mmol/L) 
 
Working reagent preparation: 
Allow the Reagent „1‟ and Reagent „2‟ to attain room temperature.  Just 
prior to use, prepare working reagent by mixing equal quantities to Reagent 1 and 
Reagent 2. 
Specimen: 
Fasting serum or heparinized plasma can be used, other anticoagulants such 
as citrate, oxalate and EDTA are unsuitable. 
Assay Parameters: 
Mode End Point 
Wavelength 1 (nm) 578 
Wavelength 2 (nm) 630 
Sample Volume (µl) 5/10 
Reagent Volume (µl) 500/100 
Incubation Time (min) 1 
Incubation Temp. (
o
C) 37 
Normal Low (mg/dl) 8.4 
Normal High (mg/dl) 10.4 
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Mode End Point 
Linearity Low(mg/dl) 0 
Linearity High(mg/dl) 20 
Concentration of Standard (mg/dl) 10 
Blank with Reagent 
Absorbance Limit (Max) 0.500 
Units (mg/dl) 
 
 
Procedure: 
Pipette into tubes marked Blank Standard Test 
Working Calcium Reagent 1000µl 1000µl 1000µl 
Distilled Water 10µl - - 
Standard - 10µl - 
Test - - 10µl 
 
Standardization: 
Pipette the following into appropriately labeled test tubes.  The contents of 
the tubes are mixed well.  The spectrophotometer is set to zero with blank at 578 
nm. 
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Pipette into tubes Blank S1 S2 S3 S4 S5 S6 Test 
Standard (µl) 0 2 4 6 8 10 12 - 
Distilled water (µl) 12 10 8 6 4 2 0 - 
Sample - - - - - - - 10 
Reagent 1000 1000 1000 1000 1000 1000 1000 1000 
Conc.Of Calcium (mg%) 0 2 4 6 8 10 12 9.28 
Absorbances 0  0.09 0.20 0.36 0.45 0.52 0.40 
  
Mix well and at 578 nm against reagent blank. 
Calculation: 
Calcium (mg/dl) =Absorbance of Test  x 10 
   Absorbance of Standard 
Normal Values: 
Normal serum calcium: 9-11 mg/dl. 
ESTIMATION OF URIC ACID BY MODIFIED TRINDER METHOD
233 
Principle: 
                           Uricase  
Uric acid+O2+H2O ---------------------- Allantoin + CO2+ H2O2
 
Peroxidase 
H2O2+ 4-AAP + TBHB --------------------------- Quinoneimine + H2O 
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The intensity of chromogen (Quinoneimine) formed is proportional to the 
uric acid concentration in the sample when measured at 546 nm. 
Reagents: 
Uric Acid Reagent: 
Active Ingredient Concentration 
4-Aminoantipyrine 0.5mmol/L 
TBHB 1.75.mmol/L 
Uricase >120U/L 
Peroxidase >500 U/L 
Tris Buffer (pH 8.25+ 0.1 at 20
o
C) 50 mmol/l 
 
 
Uric Acid Standard:   
Uric Acid Standard 6 mg/dl (0.36 mmol) 
 
 
Specimen: 
Unhemolysed serum or plasma should be separated from the cells as soon as 
possible. Recommended anticoagulants are heparin and EDTA. 
 
Assay Parameters: 
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Mode End Point 
Wavelength 1 (nm) 505 
Wavelength 2 (nm) 670 
Sample Volume (µl) 10/20 
Reagent Volume (µl) 500/1000 
Incubation Time (min) 5 
Incubation Temp. (
o
C) 37 
Normal Low (mg/dl) 2.5 
Normal High (mg/dl) 7.2 
Linearity Low (mg/dl) 0 
Linearity High (mg/dl) 25 
Mode End Point 
Concentration of Standard (mg/dl) 6 
Blank with Reagent 
Absorbance Limit (Max) 0.3 
Units  (mg/dl) 
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Procedure: 
 
Standardization: 
 Pipette the following into appropriately labelled test tubes.  The contents of 
the tubes are mixed well and incubated for 15 min.  The spectrophotometer is set to 
zero with blank at 546 nm. 
Pipette into tubes Blank S1 S2 S3 S4 S5 Test 
Standard (µl) 0 5 10 15 20 25 - 
Distilled water (µl) 20 20 15 10 5 0 - 
Sample - - - - - - 20 
Reagent 1000 1000 1000 1000 1000 1000 1000 
Conc.Of Calcium (mg %) 0 1.5 3 4.5 6 7.5 3.6 
Absorbances 0 0.36 0.72 1.05 1.44 1.80 0.86 
Mix well and incubate for 15 minutes at 37
o
C.  Read the absorbance of 
standard and each test at 546/670 nm against reagent blank. 
Pipette into tubes marked Blank Standard Test 
Working Reagent 1000µl 1000µl 1000µl 
Distilled Water 20µl - - 
Standard - 20µl - 
Test - - 20µl 
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Calculation: 
Uric Acid (mg/dl) = Absorbance of Test  x 6 
   Absorbance of Standard 
Normal Values: 
Males: 3.5 -7.2 mg/dl or 0.21-0.43 mmol/L; Females: 2.5 – 6.2 mg/dl or 0.15-0.37 
mmol/l 
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24 HOUR URINARY PROTEIN ESTIMATION 
Method: 
TCA precipitation method. 
Principle: 
Proteins in urine are denatured and precipitated as particles with TCA and are 
quantitated by measuring turbidity at 620nm. 
Reagents: 
 Sulfo Salicylic Acid 3% 
 Normal saline 
 Protein standard – bovine albumin 1g% 
 Working standard 1mg/dl to 100 mg/dl was prepared from the stock. 
Procedure: 
Three clean dry test tubes are taken and marked as „B‟ for blank „S‟ for 
standard and „T‟ for test. 1ml of distilled water is taken in B tube, 1 ml of working 
standard in S tube and 1ml of urine in T test tube. 3 ml of 3% sulfosalicylic acid is 
added to all the three test tubes. 
All the test tubes are mixed thoroughly and kept at room temperature for 10 
min. Turbidity is measured against blank at 620nm. 
Standard graph is prepared using working standard from stock. 
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Calculation: 
 
Urine protein in mg/dl = OD of T   Conc. of S  100 
             OD of S     Vol. of S 
 
24hr urine protein in mg/dl = OD of T  Conc. of S    100        24hr vol. in ml 
                    OD of S   Vol. of S   100 
 
Graph 2: 
 
Standard curve for 24 hour urinary protein 
 
 
  
STATISTICS AND 
RESULTS 
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STATISTICAL ANALYSIS 
 Data were analysed using IBM SPSS 22.5, Microsoft word and Excel have 
been used to generate graphs, tables.  
 The mean and standard deviation for all parameters. 
 The student t test – to analyse clinical and laboratory data, and the ӽ2 test 
wherever required. 
 The frequency of genotypes (TT, CT, CC) at -786 promoter region of the 
eNOS gene by using the ӽ2 test. 
 Allele frequency by using the equation p + q = 1 where p and q are the 
frequencies of each allele at the particular locus. 
 Hardy Weinberg equation equilibrium as shown by p2 + q2 + 2pq = 1. 
 The unpaired Student t test and analysis of variance to analyse the 
significance of difference in values of nitric acid in different genotypes at 
786 promoter region. 
Concept of P value 
 If the P value is 0.000 to 0.010, it implies Significant at 1 level (Highly 
Significant). 
 If the P value is 0.011 to 0.050, it implies Significant at 5 level (Significant). 
 If the P value is 0.051 to 1.000, it implies Not Significant at 5 level (Not 
Significant).  
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Baseline characteristics 
Table 1: Comparison of age, gravida and gestational age 
^ - independent t test * - Chi square test 
NS – P value not significant 
 
 
 
 
Variable  Cases 
Mean (SD) 
Control 
Mean (SD) 
P value 
Age 26.00 (0.48) 25.04 (0.51) 0.17 ^ 
Gestational age 32.86 (0.61) 33.80 (0.42) 0.21^ 
Variable Category Cases 
No (%) 
Control 
No (%) 
P value 
Gravida 1 28 (48.3%) 30 (51.7%) 0.42* 
(NS)  2 22 (52.4%) 20 (47.6%) 
Genotype CC genotype 12 (75.0%) 4 (25.0%) 0.06* 
(NS)  CT genotype 23 (59.0%) 16 (41.0%) 
 TT genotype 15 (33.3%) 30 66.7%) 
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Table 2: Comparison of biochemical parameters in cases and controls 
 group N Mean Std. Deviation P value 
SR NO Cases 50 12.44 4.73 <0.001*** (S) 
Controls  50 18.40 6.85 
SR CA Cases 50 8.44 0.79 <0.001
*** 
(S)
 
Controls  50 9.67 0.83 
UA Cases 50 6.300 1.2206 <0.001*** (S) 
Controls  50 4.224 .6690 
RBS Cases 50 90.36 11.376 0.178 (NS) 
Controls  50 87.58 8.960 
UREA Cases 50 25.86 6.446 0.694 (NS) 
Controls  50 25.38 5.689 
SR CR Cases 50 .724 .1170 0.683 (NS) 
Controls  50 .734 .1272 
S – Significant, NS – Non Significant 
Bar Diagram 1: Age Distribution in cases and controls 
 
The mean (SD) of age among the cases was 26.00(3.36) while the mean 
(SD) among the controls was 25.04(3.59). This difference was not statistically 
significant (p =0.170). 
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Table 3: UR ALB * Group 
Crosstab 
 
    Group Total 
    Control Cases   
UR ALB Nil Count 50 0 50 
    % within UR 
ALB 
100.0% .0% 100.0% 
    % within Group 100.0% .0% 50.0% 
  1+ Count 0 22 22 
    % within UR 
ALB 
.0% 100.0% 100.0% 
    % within Group .0% 44.0% 22.0% 
  2+ Count 0 28 28 
    % within UR 
ALB 
.0% 100.0% 100.0% 
    % within Group .0% 56.0% 28.0% 
Total Count 50 50 100 
  % within UR 
ALB 
50.0% 50.0% 100.0% 
  % within Group 100.0% 100.0% 100.0% 
 
 
Table 4: Chi-Square Tests 
 
  Value df 
Asymp. Sig. 
(2-sided) 
Pearson Chi-Square 100.000(a) 2 .000 
Likelihood Ratio 138.629 2 .000 
Linear-by-Linear 
Association 
82.329 1 .000 
N of Valid Cases 100     
 
a  0 cells (.0%) have expected count less than 5. The minimum expected count is 11.00. 
 
Bar Diagram 2: Urine Albumin 
 
Urine Albumin level among cases and controls were statistically significant 
by Chi-square test (P value < 0.001). 
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Table 5: T-Test – SBP / DBP 
 
Group Statistics 
 
  Group N Mean Std. Deviation 
Std. Error 
Mean 
SBP Control 50 104.60 9.521 1.346 
Cases 50 146.00 7.559 1.069 
DBP Control 50 69.40 7.117 1.007 
Cases 50 95.20 8.862 1.253 
 
 
 
Table 6: Independent Samples Test 
 
    
Levene's Test 
for Equality of 
Variances 
t-test for Equality of Means 
    F Sig. t df 
Sig.  
(2-tailed) 
Mean 
Difference 
Std. Error 
Difference 
95% Confidence Interval 
of the Difference 
                  Lower Upper 
SBP Equal 
variances 
assumed 
3.666 .058 
-
24.080 
98 .000 -41.40 1.719 -44.812 -37.988 
  Equal 
variances 
not 
assumed 
    
-
24.080 
93.208 .000 -41.40 1.719 -44.814 -37.986 
DBP Equal 
variances 
assumed 
1.127 .291 
-
16.051 
98 .000 -25.80 1.607 -28.990 -22.610 
  Equal 
variances 
not 
assumed 
    
-
16.051 
93.639 .000 -25.80 1.607 -28.992 -22.608 
 
The systolic and diastolic Blood Pressure among cases and controls was 
statistically significant by Chi-square test (P value < 0.001). 
 
  
69 
 
Table 7: Genotype 
 Cases Control Odds ratio P value 
CC + CT 35 (63.6%) 20 (36.4%) 3.5 (1.529 – 
8.012) 
0.003 (S) 
TT 15 (33.3%) 30 (66.6%) 
 
The presence of C gene in cases is 3.5 times more than that of the controls. 
The 95% confidence interval is 1.529 – 8.012 (p<0.01). 
Bar Diagram 3: Genotype   
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Table 8: Frequency of the promoter C-786 T polymorphism among 
Preeclampsia patients and controls 
 
 
Total 
X
2 
test 
Odd‟s ratio 
(95% C.I.) 
Pre-
Eclampsia 
Controls p value 
Genotype TT  15 30 45 
0.003** 
(S) 
 
 33.3% 66.7% 100.0% 0.286 (0.125 – 
0.654) CC + CT  35 20 55 
 63.6% 36.4% 100.0%  
Total  50 50 100   
 50.0% 50.0% 100.0%   
 
The frequency of the polymorphic C allele carrier which represented by 
(CC+CTG) genotypes was 63.6% in Preeclampsia patients and 36.4% in Controls.  
The frequency of wild-type TT genotype was 33.3% in Preeclampsia patients and 
66.7% in controls. The statistical analysis of frequency of C-786 T polymorphism 
among the preeclampsia patients and controls by Chi-square test showed that a 
statistical difference was evident between  two groups ( P-value <0.01, P=0.003).  
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Table 9: Allele frequencies of the eNOS gene C-786 T polymorphism among 
Preeclampsia patients and controls 
 
 
 
Total 
X
2 
test Odd‟s ratio 
(95% C.I.) Pre-eclampsia Control p value 
Allele T allele  53 76 129 
0.001** 
0.356 (0.195 
– 0.651) 
 41.1% 58.9% 100.0% 
C allele  47 24 71 
 66.2% 33.8% 100.0% 
Total  100 100 200   
 50.0% 50.0% 100.0%   
 
The frequency of the polymorphic C allele was 66.2% in Preeclampsia 
patients and 33.8% in controls.  The frequency of wild type T allele was 41.1% in 
preeclampsia patients and 58.9% in controls.  The statistical analysis of allele 
frequencies of the eNOS gene C-786 T polymorphism among Preeclampsia 
patients and controls by Chi-square test showed that there was a statistical 
significance between two groups (P value<0.001). 
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Bar Diagram 4:  Serum nitric oxide 
 
The mean (SD) levels of Serum nitric oxide among the cases was 
12.32(4.79) which was lower than the mean (SD) Serum nitric oxide levels among 
the controls, 18.40(6.85). This difference was found to be statistically significant 
by t test (p < 0.001). 
Bar Diagram 5: Serum calcium 
 
The mean (SD) levels of Serum calcium among the cases was 8.40(0.80) 
which was lower than the mean (SD) Serum calcium levels among the controls, 
9.67(0.83). This difference was found to be statistically significant by t test (p < 
0.001). 
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Bar Diagram 6: Serum uric acid 
 
The mean (SD) levels of Serum uric acid among the cases was 6.3(1.22) 
which was higher than the mean (SD) Serum uric acid levels among the controls, 
4.2(0.67). This difference was found to be statistically significant by t test (p < 
0.001). 
Bar Diagram 7: Serum Random blood sugar 
 
The mean (SD) levels of Serum Random blood sugar among the cases was 
90.36(11.38) while in the controls it was 87.58(8.96). This difference was not 
statistically significant by t test (p =0.178). 
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Bar Diagram 8: Serum urea 
 
The mean (SD) levels of Serum urea among the cases was 25.86(6.45) while 
in the controls it was 25.38(5.69). This difference was not statistically significant 
by t test (p = 0.694). 
Bar Diagram 9: Serum creatinine 
 
The mean (SD) levels of Serum creatinine among the cases was 0.72(0.12) 
while in the controls it was 0.73(0.13). This difference was not statistically 
significant by t test (p =0.683). 
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Master Chart 1: Cases 
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Master Chart 2: Controls 
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RESULTS 
 
 Master Charts 1 & 2 give the various data about the case and control 
groups respectively. Table 1 shows the baseline characters of variables such 
as age, gestational age, gravida and genotype. Table 2 shows the bio 
chemical parameters in cases and controls. 
 Bar Diagram 1 is related to Age which reveals that the mean (SD) of 
age among the cases was 26.00(3.36) while the mean (SD) among the 
controls was 25.04 (3.59). This difference was not statistically significant  
(p =0.170). 
 Table 3 & 4 and Bar Diagram 2 is related to Urine Albumin level 
from which it is found that Urine Albumin level among cases and controls 
was statistically significant by Chi-square test  (P value < 0.001). 
 Table 5 & 6: T-Test is related to SBP / DBP from which it is found 
that the systolic and diastolic Blood Pressure among cases and controls was 
statistically significant by Chi-square test (P value < 0.001). 
 Table 7 and Bar Diagram 3 are related to Genotype from which it is 
found that the presence of C gene in cases is 3.5 times more than that of the 
controls. The 95% confidence interval is 1.529 – 8.012 (P < 0.01). 
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  Table 8 shows the frequency of the promoter C-786 T polymorphism among 
Preeclampsia patients and controls 
Cases: 
   TT: 33.3%  CC+CT: 63.6% 
  Controls: 
   TT: 66.7%  CC+CT: 36.4% P value 0.003 (P<0.01) (S) 
  Table 9 shows Allele frequencies of the eNOS gene C-786 T polymorphism 
among Preeclampsia patients and controls 
Cases: 
 T Allele: 41.1% C Allele: 66.2%  
Controls: 
 T Allele: 58.9% C Allele: 33.8% P value < 0.001 (S) 
  Bar Diagram 4 is related to Serum Nitric Oxide from which it is found that 
the mean (SD) levels of Serum nitric oxide among the cases was 12.32(4.79) which 
was lower than the mean (SD) Serum nitric oxide levels among the controls, 
18.40(6.85). This difference was found to be statistically significant by t test  
(P < 0.001). 
  Bar Diagram 5 is related to Serum Calcium from which it is found that the 
mean (SD) levels of Serum calcium among the cases was 8.40(0.80) which was 
lower than the mean (SD) Serum calcium levels among the controls, 9.67(0.83). 
This difference was found to be statistically significant by t test (p < 0.001). 
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  Bar Diagram 6 is related to Serum Uric Acid level from which it is found 
that the mean (SD) levels of Serum uric acid among the cases was 6.3(1.22) which 
was higher than the mean (SD) Serum uric acid levels among the controls, 
4.2(0.67). This difference was found to be statistically significant by t test 
(p<0.001). 
  Bar Diagram 7 is related to Serum RBS from which it is found that the mean 
(SD) levels of Serum Random blood sugar among the cases was 90.36(11.38) 
while in the controls it was 87.58(8.96). This difference was not statistically 
significant by t test (p =0.178). 
  Bar Diagram 8 is related to Serum Urea level from which it is found that the 
mean (SD) levels of Serum urea among the cases was 25.86(6.45) while in the 
controls it was 25.38(5.69). This difference was not statistically significant by t test 
(p = 0.694). 
  Bar Diagram 9 is related to Serum Creatinine from which it is found that the 
mean (SD) levels of Serum creatinine among the cases was 0.72(0.12) while in the 
controls it was 0.73(0.13). This difference was not statistically significant by t test 
(p =0.683). 
  
 
 
 
 
DISCUSSION 
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DISCUSSION 
Preeclampsia is an important clinical and stressful problem that has been 
studied tremendously but the causes and treatment have not been fully resolved 
130
. 
Preeclampsia affects about 1-5% of women who conceive 
131
 and accounts for 
about 20% of clinically recognized pregnancy losses 
132
. Despite extensive 
researches to explain the causative effects of Preeclampsia, about 50% - 60% of 
Preeclampsia is still idiopathic. Endothelial damage, impaired placental 
vascularization and resultant oxidative stress have been proposed to play a role in 
the pathophysiology of Preeclampsia. 
In case of normal pregnancy, the Nitric Oxide pathway is activated and leads 
to increased NO availability and level which is further responsible for maternal 
vasodilation required to accommodate the increase in circulating volume during 
pregnancy without a rise in blood pressure 
133
. eNOS has been regarded as the 
source of endothelial NO, which has a critical role in vascular physiology and 
impaired placental vascularization 
134
. In recent years much attention was paid to 
determine the association between eNOS gene 786 T (Promoter) allelic variants 
and preeclampsia. However, the results of the studies have been controversial 
among different ethnic groups 
135
.  
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Few studies have investigated the relation between eNOS promoter C-786 T 
polymorphism and the development of Preeclampsia and other reproductive 
complications in women from various populations. Our results for the promoter   
C-786 T polymorphisms are in agreement with those published by Shim, et al 
(2010) who showed that the promoter C-786 T polymorphism is associated with 
the risk of spontaneously aborted foetuses. This result is also consistent with those 
recorded for Indian women origin where a significant association between the      
C-786 T promoter and preeclamptic pregnancy complication was observed. 
In contrast, our results do not support the previously published results for 
women from Korean and Tunisian populations
136
 which indicated that C-786 T 
promoter  polymorphisms is not significantly associated with Preeclampsia. 
Frequency of the promoter C-786 T polymorphism among Preeclampsia 
patients and controls: 
The table 8 reveals that the frequency of the polymorphic C allele carrier 
which represented by (CC+CTG) genotypes was 63.6% in Preeclampsia patients 
and 36.4% in Controls.  The frequency of wild-type TT genotype was 33.3% in 
Preeclampsia patients and 66.7% in controls. The statistical analysis of frequency 
of C-786 T polymorphism among the preeclampsia patients and controls by Chi-
square test showed that a statistical difference was evident between  two groups     
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(P-value <0.01, P=0.003). The Odds ratio with 95% confidence interval is 3.5 
which indicate the presence of polymorphic C allele in cases 3.5 times more than 
that of controls. 
Allele frequencies of the eNOS gene C-786 T polymorphism among 
Preeclampsia patients and controls: 
The table 9 reveals that the frequency of the polymorphic C allele was 
66.2% in Preeclampsia patients and 33.8% in controls.  The frequency of wild type 
T allele was 41.1% in preeclampsia patients and 58.9% in controls.  The statistical 
analysis of allele frequencies of the eNOS gene C-786 T polymorphism among 
Preeclampsia patients and controls by Chi-square test showed that there was a 
statistical significance between two groups (P value<0.001). 
The findings regarding eNOS polymorphism and its association with 
Preeclampsia clearly showed that eNOS gene C-786 T polymorphism, namely 
“allele-786C”is associated with Preeclampsia in our study population. 
Association of eNOS C-786 T polymorphism and Nitric Oxide Synthesis: 
As per Bar Diagram 4, the results of present study showed that C-786 T 
polymorphism is associated with low Serum Nitric Oxide level. The mean (SD) 
level of Serum Nitric Oxide among the cases was 12.32 (4.79) lower than the mean 
(SD) Serum Nitric Oxide level among the controls which was 18.40 (6.85). This 
difference was found to be statistically significant by t test (P<0.001). 
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The study showed that promoter C-786 T substitution markedly blunts the 
transcription rate of eNOS gene and hence the Nitric Oxide production by creating 
a binding site for a Replication Protein A1 (RPA1) by C allele that acts as a 
suppressor of eNOS transcription. 
The RPA1 protein is not only in endothelial cells but also in placenta which 
is rich in vasculature and the level of eNOS mRNA in placenta with promoter      
C-786 T substitution mutation is significantly lower than in placenta without 
mutation.  
These findings confirm our results that preeclampsia women are associated 
with high frequency of promoter C-786 T polymorphism. It explains the 
association between the polymorphism and Serum Nitric Oxide level. 
Since Nitric Oxide pathway plays an important role in the pathophysiology 
of Preeclampsia, any factors balancing Nitric Oxide metabolism could be useful in 
the treatment of Preeclampsia, thus reducing maternal and foetal morbidity and 
mortality. 
These findings confirm our results that Preeclampsia women are associated 
with a high frequency of promoter-786T (Promoter) allelic variants might explain 
why this polymorphism is associated with a low serum NO levels. 
  The table 4 and 5 show the significant statistical difference between cases 
and controls (P value < 0.001).  
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  The Bar Diagrams 5 and 6 show that the mean (SD) levels of Serum calcium 
and Uric Acid among the cases were lower than the controls.  These were found to 
be statistically significant by t test (p < 0.001). 
  The Bar Diagrams 7, 8 and 9 show that the mean (SD) levels of Serum 
Random blood sugar, Urea and Creatinine among the cases were lower than the 
controls.  These differences were not statistically significant by t test (p =0.178, 
0.694 and 0.683 respectively). 
The present data add to the importance of ethnic as well as intraregional 
variability in such studies concerning multifactorial disorders including 
preeclampsia.  Our findings regarding the eNOS polymorphisms and its association 
with preeclampsia clearly showed that the promoter C-786T polymorphism of the 
eNOS gene, namely “allele -786C” is associated with preeclampsia in our study 
population.  
We recommend for testing the promoter -786T (Promoter) allelic variants 
polymorphism of eNOS gene in all Indian women experiencing preeclampsia or 
unexplained hypertension during pregnancy. Since NO pathway plays an important 
role in the pathophysiology of preeclampsia, thus, any factors balancing NO 
metabolism could be useful in the treatment of preeclampsia, consequently, 
reducing the substantial morbidity and associated maternal and fetal mortality.  
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The rapid accumulation of advanced knowledge in genetics and molecular 
biology as well as fast progress in diagnostic methods enabled to distinguish a new 
research field called molecular medicine. Nowadays molecular biology methods 
are the core applications used in investigations concerning etiology of numerous 
complex human diseases and contribute to gene therapy development. A key 
method used in that kind of diagnostics are polymerase chain reaction (PCR) – 
based applications which are characterized by much higher sensitivity and 
specificity than classical diagnostics 
137
. 
Many issues of molecular biology consider problems from obstetrical and 
gynecological field. There have been revealed numerous gene polymorphisms 
which are favourable to clear some pregnancy complications and gynecological 
diseases 
138
.  
It is also suggested that some genetic variants may be the markers of 
increased risk of several diseases in pregnant women as well as in gynaecologic 
disturbances. Typical example of the practice of molecular biology methods are 
investigations on the osteoporosis field. 
Nowadays, the analysis of candidate genes is one of the study ways of 
genetic background of etiology in preeclampsia (PE). The candidate gene is a gene 
of documented biological activity involved in the PE pathways, with polymorphic 
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activity. This process is one of the conditions of inter-individual variability. At 
present there are more than sixty candidate genes to PE development. It was 
distinguished some groups of candidate genes in PE pathophysiology. 
Family-based studies have shown that genetic factors may play a role in 
preeclampsia 
139
. In addition, candidate-gene association studies (GAS) on 
preeclampsia have not produced conclusive results so far 
140
. However, the 
pathogenesis of preeclampsia is poorly understood and the search for low-
penetrance genes by hypothesis-driven candidate gene studies (genetic association 
study-GAS) and hypothesis-free genome-wide association studies is ongoing 
141
.  
The leading hypotheses, concerning the pathogenesis of preeclampsia, are 
based on disturbed placental function and impaired remodelling of the spiral 
arteries 
142
.  
Endothelial nitric oxide synthase (NOS3) is an important regulator of 
vascular tone and contributes to the reduction of the uteroplacental resistance seen 
in normal pregnancy 
143
. Therefore, the endothelial nitric oxide synthase gene 
(NOS3), located at the 7q35-q36 region, has emerged as a logical candidate gene in 
the development of preeclampsia. Variants (polymorphisms) of the NOS3 gene 
have been investigated for association with preeclampsia and other disorders such 
as hypertension. 
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Endothelial dysfunction, as a syndrome, is defined as the absence of 
antithrombotic, angiogenic, inflammatory and vasodilator functions of 
endothelium. Evidences from documented cases have revealed that the bioactivity 
or bioavailability of nitric oxide (NO) is reduced in this condition, and, in turn, 
vasodilator capacity and vascular protection against harmful agents is impaired. 
The NO is a powerful endogenous vasodilator, which performs key roles in blood 
pressure regulation, vascular dilation, vascular smooth-muscle proliferation and 
inhibition of platelet aggregation. These abilities recommend this molecule as an 
attractive candidate for predisposition to Preeclampsia.  
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SUMMARY 
Association of eNOS gene polymorphism, Nitric Oxide Synthesis & 
Preeclampsia: 
 
e Nitric Oxide Synthase  gene promoter C – 786T  Polymorphism 
 
C  allele creates a binding site for a Replication Protein A1 (RPA1) 
 
Suppression of eNOS transcription 
 
Decrease in  eNOS enzyme activity 
 
Reduction of Nitric Oxide production 
 
Low serum levels of Nitric Oxide 
 
Risk factor for Preeclampsia 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
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CONCLUSION 
 
 In this study, C allele was significantly increased in Cases compared to Controls 
which implies that the presence of C allele in C-786 T promoter polymorphism 
of eNOS gene found to be the risk factor for Preeclampsia. 
 The presence of polymorphic C allele in C-786 T promoter polymorphism of 
eNOS gene was found to have an effect on Serum Nitric Oxide levels by 
altering the transcriptional efficiency which led to decrease in endothelial Nitric 
Oxide synthase enzyme activity thereby reducing Nitric Oxide production. 
 Hence, the Nitric Oxide level in serum was low which may be an independent 
risk factor for preeclampsia. 
 So, it may be concluded that there is an association between eNOS gene 
polymorphism (C-786 T promoter), low Nitric Oxide level and Preeclampsia. 
  
  
 
 
 
 
 
 
FUTURE SCOPE OF 
STUDY 
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FUTURE SCOPE OF STUDY 
 
 Genetic differences across different ethnic groups for this polymorphic site 
(C-T786 promoter of eNOS gene) have to be established. 
 The Nitric Oxide level may be estimated in routine antenatal investigations 
for Pregnancy Induced Hypertensive (PIH) patients. 
 By taking large sample size for genetic polymorphic studies in PIH women, 
we can segregate high risk group of patients to focus on their diet and life 
style modification for safe confinement. 
 Further research may focus upon gene – gene interactions and gene 
environmental interactions and its relationship with genotypic variation of 
eNOS gene in patients with Preeclampsia so as to provide efficient 
preventive measures in genetically susceptible population in future. 
 The whole genome sequence analysis is needed to reveal extensive level of 
variation and heterogeneity between individuals and populations. 
 Genome- Wide Association Studies (GWAS) has to be carried out, as these 
analyses eliminate biases in the selection of candidate genes. 
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ANNEXURES 
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PROFORMA 
       Date: 
Name:                                                                              OP/IP No: 
Age:                                                                                  Sex          : 
Address:                                                                        Occupation:    
                                                                                     
Presenting Complaints:                                                             
 
Past H/O:   
Smokers, Renal disease, Chronic illness, Diabetes mellitus, Systemic hypertension, 
Acute/Chronic infection 
 Treatment H/O:  
 
Previous hospitalization: 
 
Personal H/O: 
                                SMOKING   / ALCOHOL INTAKE 
O/E:  
 
Built -               
Height-      
Weight-   
Pedal edema /Anemia/Clubbing /Lymphadenopathy 
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VITALS:     
BP:                                                                         
Pulse Rate: 
SYSTEMIC EXAMINATION : 
CVS:                                                                        Abdomen:    
 RS :                                                                                   CNS: 
Diagnosis: 
 
Investigations: 
1. Blood sugar 
2. Urea 
3. Creatinine 
4.Uric acid 
5.Serum Nitric oxide   
6.Urine microprotein 
7.Serum calcium  
7.Genetic polymorphic studies 
 
 DNA EXTRACTION 
 GENOMIC DNA  AMPLIFICATION  BY PCR  
 2% AGAROSE GEL RUN 
 RESTRICTION DIGESTION OF THE PCR PRODUCT 
 Genotype : 
 TT/CT/CC: 
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Master Chart - Cases 
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Master Chart - Controls 
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